The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic https://mixbookmark.com/story6350062/retatrutide-vs-tirzepatide-a-comparative-analysis